A bullish Ark Invest on Wednesday more than doubled its stake in Zymergen Inc (NASDAQ: ZY) after it plummeted due to the company’s “immaterial” revenue warning.
The coronavirus pandemic that began in 2020 and is persisting today has led many investors to hold poor market expectations. But maybe they shouldn’t be so pessimistic.
Cathie Wood-led Ark Investment Management on Wednesday piled up 713,842 shares, estimated to be worth about $108.37 million, in Teladoc Health Inc (NYSE: TDOC), a day after the telemedicine company
ARK Invest, the New York-based investment management firm led by the popular money manager Cathie Wood, saw its five actively managed exchange-traded funds and two self-indexed ETFs underperform the S&P 500 index in the second quarter.
Cathie Wood-led Ark Investment Management on Tuesday snapped up 858,129 shares, estimated to be worth about $59.12 million, in UiPath Inc (NYSE: PATH) on the dip.
Shares of the New York-based software automation company closed 3.34% lower at $68.90 on Tuesday.
Cathie Wood-led Ark Investment Management on Friday snapped up 136,859 shares, estimated to be worth about $9.55 million, in UiPath Inc (NYSE: PATH).
Shares of the New York-based software automation company closed 1.04% higher at $69.77 on Friday.
Cathie Wood-led Ark Investment Management has quickly piled up over one million shares in the semiconductor company Quantum-Si Inc (NASDAQ: QSI) since it began trading earlier this month.
Cathie Wood-led Ark Investment Management on Thursday snapped up more shares in Coinbase Global Inc (NASDAQ: COIN) on the dip on Thursday.
Ark Invest bought 60,813 shares, estimated to be worth about $13.5 million in Coinbase on the day shares of the company closed 1.1% lower at $221.85.
Cathie Wood-led Ark Investment Management on Wednesday significantly raised its stake in Intuitive Surgical Inc (NASDAQ: ISRG) as it bought 7,259 shares of the robotic medical equipment maker, estimated to be worth about $5.96 million.
Cathie Wood-led Ark Investment Management is betting that despite recent setbacks Iovance Biotherapeutics Inc (NASDAQ: IOVA) will benefit from its compelling tumor-infiltrating lymphocyte (TIL) immunotherapy.